Clinical trial
Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1…
NCT00265395 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00265395 |
|---|---|
| Title | Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685) |
| Official title | A Study to Assess Treatment With PEG-Intron® and Rebetol® in Naïve Patients With Genotype 1 Chronic Hepatitis C and Slow Virological Response |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®), Combination of pegylated interferon alfa-2b and ribavirin |
| Enrollment | 1,428 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Dec 14, 2005 |
| Last update posted | Apr 5, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: